TransMedics Group is trading 4.1% higher at $83.58, with no clear company-specific catalyst identified. - The gain comes as major indexes fall; healthcare is up 1.25%, and sector context points to defensive-sector demand. This may be a supporting factor but does not establish a specific cause for the stock’s move. - The latest company release found was its September 28 CFO appointment and reaffirmed 2026 outlook.